eyeforpharma The Marketing Disruption Summit

eyeforpharma2 - 3 October 2019, Philadelphia, USA.
It's 2019 and Marketing is changing. Your customers' expectations have shifted to ‘one-click’. They expect more, they’re used to intuitive consumer interactions, and now they're looking at pharma.

Providing the seamless, personalized experience you've been dreaming about has never seemed closer. But marketers can't do it alone.

The Marketing Disruption Summit attendance is already ahead of expectations, with groups of industry leaders from across Marketing, Strategy, Data and IT already booked to delve deep into specifics with talks, workshops and case studies from top pharma, and equip themselves to be the key changemakers at home.

On current predictions, tickets will sell out this year. Ensure you have a place reserved at the only event where pharma marketing, data & IT change makers redefine customer interaction.

Reach out like never before

With Industry Leading Speakers carefully selected to cover every aspect of the back and front-end customer cycle, and an agenda designed to provide solutions to all the collaborative problems holding back your customer engagement:

Including:

  • Martina Flammer SVP customer value, Boehringer Ingelheim
  • Krishna Cheriath Chief Data Officer BMS
  • Alessandra Almeida Snr Director, Global Head of Master Data Management, Sanofi
  • Ignacio Quiles lara exec director global marketing and commercial ops, Abbvie
  • Ramon Vega head of global pharma marketing IT, Merck
  • Renaud Sermondade Head of insights and analytics, Sanofi

Unite to exceed changing customer demands

Marketers: Understand the technical capabilities within your business, build results-based strategies, and unite teams behind your vision.

Data: Communicate your capabilities and gain vital authority in strategic conversations.

Technology: Show stakeholders what your internal teams can do and inspire new strategies with innovation.

Together: Build cross functional strategies to revolutionize, personalize and redefine customer interaction.

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save $300 when you register here

For further information, please visit:
https://www.eyeforpharma.com/marketingusa/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...